Society of Surgical Oncology 2026 Annual Meeting
March 5-7, 2026 | Phoenix, Arizona
Quest Diagnostics® booth 205
The Haystack MRD® team will be on-site at the 2026 SSO Annual Meeting. Connect with our medical and commercial teams to learn how our exceptionally accurate minimal residual disease (MRD) testing provides confident results to support decision-making across oncology settings. We’ll be at Quest Diagnostics® booth 205.
Featured presentation
We’re excited to share that Dr Thomas “TJ” Slavin, MD, MBA will be presenting a talk:
Assessing risk across neoadjuvant and post-surgical settings: How Haystack MRD® helps enable confident care decisions
Date: Thursday, March 5
Time: 3:35 PM – 3:55 PM
Location: HUB Theater
This session will explore how circulating tumor DNA (ctDNA) insights can help inform risk assessment and care planning before and after surgery, supporting more individualized decision-making across the treatment continuum.
Visit us at booth 205
Stop by Quest Diagnostics booth 205 to:
- Discuss integration of ctDNA testing into patient care pathways before and after surgery
- Learn how Haystack MRD brings confident insights into solid tumor risk assessment with real-world case studies
- Connect with members of our medical and commercial teams attending SSO 2026
We’re looking forward to connecting with surgical oncologists and multidisciplinary care teams to discuss how Haystack MRD can support confident risk assessment before and after surgery.
About Haystack MRD
Haystack MRD is a highly sensitive, tumor-informed ctDNA assay designed to detect ultralow levels of minimal residual disease with superb accuracy. With patented error-correction technology to reduce sequencing noise, Haystack MRD provides confidence in results to help guide care decisions across key moments in the cancer journey.
